The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer
- Resource Type
- Authors
- Özlem Kaymaz; Ismail Selvi; Halil Başar; Numan Baydilli; Koza Murat
- Source
- International Urology and Nephrology. 51:1975-1983
- Subject
- Male
Nephrology
medicine.medical_specialty
Prostate biopsy
Arginine
Urology
Urinary system
030232 urology & nephrology
030204 cardiovascular system & hematology
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
Predictive Value of Tests
Internal medicine
Biopsy
Biomarkers, Tumor
medicine
Humans
Prospective Studies
Aged
Tumor marker
medicine.diagnostic_test
business.industry
Prostatic Neoplasms
Middle Aged
Ornithine
Prognosis
medicine.disease
chemistry
business
- Language
- ISSN
- 1573-2584
0301-1623
There is still no certain threshold value of prostate-specific antigen (PSA) for prostate cancer diagnosis. We aimed to investigate the predictive value of arginine and its metabolites for diagnosing prostate cancer in patients with PSA 4–10 ng/ml and evaluate their usefulness as prognostic tumor markers. Seventy-eight patients with a mean age of 64.50 ± 5.49 years were included in our prospective observational study between November 2016 and March 2017. They were divided into two equal groups according to the pathologic results of prostate biopsy (benign vs. malignant). Plasma arginine and ornithine levels were analyzed before biopsy by liquid chromatography–tandem mass spectrometry. ELISA was used for analyzing urinary diacetylspermine. In PSA-adjusted analysis, the malignant group had lower plasma arginine levels (p = 0.021) and arginine to ornithine ratio (AOR) (p = 0.010), but higher plasma ornithine levels (p = 0.012) and urinary diacetylspermine levels (p